Coagulation Factor V
Activation of Factor V by Alpha-Thrombin
The activation of single chain factor V (330,000) by alpha-thrombin is represented. Arrows indicate the site at which factor V is cleaved by thrombin to yield two activation peptides (71,000 and 120,000), in addition to the heavy (94,000) and light (74,000) chains which form Va. The heavy and light chains of factor Va remain non-covalently associated in the presence of calcium ions.
Price $302.00/50 µg ($272.00/min. 5)
Size 50 µg Formulation 50% glycerol/water (v/v) Storage -20°C Purity >95% by SDS-PAGE Activity Determination Clotting assay Shelf Life (properly stored) 6 months
Price $302.00/100 µg ($272.00/min. 5)
Size 100 µg Formulation 50% glycerol/water (v/v) Storage -20°C Purity >95% by SDS-PAGE Activity Determination Clotting assay Shelf Life (properly stored) 6 months
Factor V is a large, single chain, plasma glycoprotein which is an essential component in the blood coagulation cascade (1). During coagulation, the procofactor, factor V, is converted to the active cofactor, factor Va, via limited proteolysis by the serine protease alpha-thrombin (illustrated above), and less efficiently by factor Xa. The active cofactor is composed of an NH2-terminal derived heavy chain (Mr=94,000) and a COOH-terminal derived light chain (Mr=74,000) which remain non-covalently associated in the presence of calcium ions. Factor Va serves as a cofactor for the serine protease factor Xa. Factor Va and Xa assemble on a phospholipid surface in a non-covalent and calcium ion-dependent manner, to form the prothrombinase complex. The prothrombinase complex is responsible for the rapid conversion of the zymogen prothrombin to the active serine protease, alpha-thrombin. Assembly of the prothrombinase complex increases the rate at which prothrombin is converted to thrombin by nearly 300,000-fold relative to the rate with factor Xa alone. Down regulation of the prothrombinase complex is accomplished partly through the inactivation of factor Va by activated protein C.
Human factor V is prepared from fresh frozen human plasma using immunoaffinity chromatography as described by Katzmann and coworkers (2). Bovine factor V is prepared from fresh bovine plasma using conventional chromatographic techniques as described by Nesheim and coworkers (3). Purified factor V is supplied in 50% glycerol (vol/vol), and should be stored at -20°C. Purity is determined by SDS-PAGE analysis and activity is measured in a factor V clotting assay.
|Gel||Novex 4-12% Bis-Tris|
|Load||Human Factor V, 1 µg per lane|
|Standard||SeeBluePlus 2; Myosin (191 kDa), Phosphorylase B (97 kDa), BSA (64 kDa), Glutamic Dehydrogenase (51 kDa), Alcohol Dehydrogenase (39 kDa), Carbonic Anhydrase (28 kDa), Myoglobin Red (19 kDa), Lysozyme (14 kDa)|
|Special Notes||Factor V is a very labile protein. Some degraded fragments are usually noticeable in preparations.|
|Localization||Plasma and platelets|
|Plasma concentration||7.0 µg/ml (human) (4,5)
35 µg/ml (bovine) (5)
|Mode of action||Procofactor; activated by thrombin to form the active cofactor, factor Va|
|Molecular weight||330,000 (3) - (determined for bovine factor V)|
|Structure||one subunit, 2196 amino acids (1,6) - (determined for human factor V)|
|Percent carbohydrate||approximately 25% (based upon the calculated molecular weight of human factor V)|
- Mann, K.G., et al., Ann. Rev. Biochem., 57, 915 (1988).
- Katzmann, J.A., et al., Proc. Natl. Acad. Sci. USA, 78, 162 (1981).
- Nesheim, M.E., et al., J. Biol. Chem., 254, 508 (1979).
- Tracy, P.B., et al., Blood, 60, 59 (1982).
- Nesheim, M.E., et al., Methods Enzymol., 80, 249 (1981).
- Jenny, R.J., et al., Proc. Natl. Acad. Sci. USA, 84, 4846 (1987).
- Ofosu, F., et al., Biochem. J. (1992) 283, 893–897. (Factor V Activation)
- Ainle, F., et al., Blood. 2009 114: 1658-1665 (Inhibition of Factor V activation)
- Weeterings, C., et al., Blood 2008 112: 3227-3233 (Thrombin generation)
- Yang, X., et al, Biochem. J. (1990) 272, 399-406 (Activation of Factor V)
This publication list is not all encompassing, and is only meant to provide limited examples of how Haematologic Technologies' products are used. We encourage you to search the literature for other examples pertinent to your experimentation, and to contact us with any technical questions.